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ABSTRACT
Phototherapy is a therapeutic strategy in dermatology for treating several skin diseases.
Conventional phototherapy has some disadvantages, hence a targeted phototherapy that emits
selective laser or ultraviolet (UV) light and targets specific area of affacted skin has been developed.
Targeted phototherapy is considered to be more aggressive and has higher efficacy. Several
targeted phototherapy devices emit one or several types of light. The use of targeted phototherapy
has been studied in vitiligo, psoriasis, eczema, keloid, hypopigmented scar or striae alba, and
oral lichen planus.
ABSTRAK
Fototerapi merupakan salah satu strategi pengobatan dalam bidang dermatologi untuk terapi
beberapa penyakit kulit. Fototerapi konvensional memiliki beberapa kekurangan sehingga
dikembangkan targeted phototherapy yang dapat mengeluarkan laser atau sinar ultraviolet dan
ditujukan hanya pada area kulit yang terlibat. Targeted phototherapy dipertimbangkan lebih
agresif dan memiliki efikasi yang tinggi. Beberapa sediaan alat targeted phototherapy dapat
memancarkan satu atau lebih jenis sinar. Penggunaan targeted phototherapy telah diteliti pada
kasus vitiligo, psoriasis, eksema, keloid, skar hipopigmentasi atau striae alba, dan lichen planus
oral.
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INTRODUCTION
Phototherapy is a therapeutic strategy in
dermatology for treating several skin diseases.1,2
Conventional phototherapy uses a whole body
cabinet or body part machine such as hand, foot
or scalp machines, which results in exposure to
unaffected body area. Not to mention, it is the
slow irradiation system that causes a prolonged
therapy session and the more frequent clinical
visits. Other disadvantages in using
conventional phototherapy are the inability to
reach particular body such as genital area and
skin folds, the distress of providing therapy for
children who are not comfortable with a vast
machine and the larger space required for
placing the machine.1
Due to those disadvantages of conventional
phototherapy, a new phototherapy technique was
then developed to overcome this situation. This
technique was called targeted phototherapy or
also known as concentrated phototherapy,
focused phototherapy, microphototherapy and
localized phototherapy. Targeted phototherapy
is defined as a therapeutic method using a device
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that delivers laser light or ultraviolet light
spectrum of a specific wavelength focused on
specific body areas or lesions.1,3 This definition
includes different technologies used such as
excimer laser, intense pulse light system (IPL)
and ultraviolet (UV) light source with a
sophisticated delivery system which is easy to
be operated by hands.1
This literature review discusses the targeted
UV light phototherapy and the excimer laser,
their advantages, type of devices, and also their
usage in dermatology, in the aim to broaden our
knowledge of therapeutic strategy so that a
precise and appropriate therapeutical decision
can be made.
DISCUSSION
Phototherapy Mechanism ofAction
Ultraviolet light has a spectrum which is
divided into 3 parts according to their
wavelengths, namely UVC with the shortest
wavelength (200-290 nm), UVB with the
intermediate wavelength (290-320 nm) and UVA
with the longest wavelength (320 -400 nm). UVA
is then divided into UVA1 (340-400 nm) and
UVA2 (320-340 nm).4,5 The light sources include
broadband UVB (BB-UVB) with a wavelength
of 290-320 and a peak at 313 nm, narrowband
UVB (NB-UVB) with a wavelength of 311-313
nm, UVA (320-400 nm, peaks at 355 nm), and
UVA1 (340-400 nm, peaks at 365 nm).4 Excimer
laser which emits monochromatic UV light, has
various wavelength ranges depending on the
molecules used, especially in the field of
dermatology XeCl laser with a wavelength of
308 nm.1
Various mechanisms were found and it was
proposed that phototherapy can give either in
systemic or local effect. Ultraviolet B rays have
shorter wavelengths so that they do not penetrate
as deeply as UVA rays do, but UVB rays have
more energy. Ultraviolet B phototherapy primer
effect is on the function of keratinocytes and
Langerhans cells. The effectiveness of UVB
therapy in psoriasis especially lies on its
anti prol i f erati ve ef f ect.6 The decrease of
pruritus after the treatment with both BB-UVB
UVB and NB-UVB is caused by cell mast
apoptosis.7 In the use of targeted BB UVB
phototherapy,6 NB UVB8 and excimer laser,9,10
T cell apoptosis was found. The apoptosis
mechanism may be caused by the damage of the
epidermis and dermis cells which are
susceptible to UV light exposure. Ultraviolet B
rays cause DNA damage and formation of
pyrimidine dimer.11 In addition to T cell
apoptosis, UVB radiation triggers changes in
cytokine production, local immunosuppression,
stimulation of melanocyte-stimulating hormone
(MSH), increases migration, proliferation of
melanocytes and melanogenesis.12,13
Ultraviolet A has a longer wavelength, so
it can reach the dermis and have an effect on
fibroblasts, dermal dendritic cells, endothelial
cells, T lymphocytes in the dermis and
granulocytes.4 In atopic dermatitis, UVA is
shown to cause apoptosis of T helper cells in
the skin with eczema lesions through FAS/FAS-
ligand system.14 In addition, UVA and UVA1-
irradiation may also decrease histamine release
by basophils and mast cells.15 The combination
between UVAand psoralen (PUVA) has a more
complex mechanism. Psoralen undergoes
intercalation in the double-stranded DNA.
Ultraviolet A exposure causes the formation of
3,4 or 4',5' cyclobutane monoadduct with
pyrimidine bases on a single photon absorption.
The double helix DNA then undergoes a cross-
linking process when the absorbed second light
photon by 2 monoadducts forming a bifunctional
adduct. DNA replication is inhibited by the
cross-linking results in cell cycle disruption and
decreased epidermal proliferation. Once
psoralen excitated by the photons, it can react
with oxygen molecules to form reactive oxygen
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species (ROS), which can cause mitochondrial
dysfunction and apoptosis of Langerhans cells,
keratinocytes and lymphocytes.5
Both UVA and UVB cause decreased
expression of ICAM-14 and increased levels of
immunosuppressive cis-urocanic acid that it can
depress cellular immune response and inhibit
Langerhans cells activities.16The mechanism of
action of targeted phototherapy is similar to the
mechanism of action of conventional UVB/UVA
phototherapy, but is thought to be more
aggressive because the dose given can be higher
than the erythemogenic dose, which results in a
greater efficacy due to its ability to deliver the
energy to the deeper dermis layer.1
Targeted Phototherapy Device Availability
Targeted phototherapy device consists of 2
parts, a generator that generates the UV light,
and a probe connected to the generator via an
optical fiber cable that is easy to be operated
by hands. Several other tools have probes with
lamps connected to the adaptors via cables.
Some UV light-based targeted phototherapy
preparations that emit one type of light and have
been used on researches are BClear (Lumenis
Inc., Santa Clara, CA, USA; emitting UVB
light),17,18 Bioskin® (Centro Salute Montecani
S.r.l., Montecatini Terme, Italia; emitting UVB
light),19,20 Biopsorin (emitting NB-UVB light),21
The Resolve™ (Allux Medical Inc., Menlo
Park, CA, USA; emitting UVB light),22 NEC
lighting flat type NB-UVB (NEC lighting,
Tokyo, Japan; emitting NB-UVB light), 23
Dermalight 80 Psoracomb (Dr R. Hönle,
Munich, Germany; emitting UVB, NB-UVB or
UVA light),24 DermaPAL™ (Daavlin, Ohio,
USA; there are 3 preparations provided, UVA,
UVB and NBUVB).
There are some targeted phototherapy
preparations that are able to emit more than one
type of light, they are DuaLight™ (TheraLight,
Inc., Carlsbad, CA, USA; emitting UVB (BB or
NB-UVB) and UVA light), 25 MultiClear
(Curelight Ltd, Israel; emitting the combination
of light between UVB (296-315 nm), UVA1
(360-370 nm) and intense blue light),26 Psoria-
Light™ Model PSI 1000: (emitting UVA and
UVB light).
Excimer lasers which have been utilized
on some researches and available in the market
are Talos (Wavelight Laser Technologie,
Jerman)9, Excilite-Deka (Florence, Italia)10, and
Xtrac (Photomedex, Radnor, PA, USA).27
The Benefits of Using Targeted
Phototherapy
Some of the advantages of using targeted
phototherapy for the patients are that the
exposure is confined to the affected skin area,
hence minimizing the acute side effect such as
erythema as well as the chronic side effect such
as skin cancer on the unaffected skin area,1,17-
24,26-30 the quick energy delivery of targeted
phototherapy surely shortens each therapy
session.1,26,27 Unlike conventional phototherapy,
it has the ability to reach difficult area of the
body such as genital, scalp, ear and other area
with skin folds1,17,19,20,24 and the dosage can be
tailored depending on the affected area or
lesion,9,17,19,31 so that therapeutic effect is
achieved faster.All mentioned advantages result
in less frequent clinical visits,1 and increased
comfort, especially for children patient.30 The
highlight of this device is that it can be used
safely at home.22
For the doctors or the operators, the
advantages of targeted phototherapy are that the
device is easy to operate,1,17 has the ability to
do a good targeted PUVA,17can be administered
with different doses for different body
parts,19.20,24 and does not need special electricity
tools.1 It also has a countertop design, does not
need vast space to place the device, and is easy
to perform minimal erythema dose (MED) or
minimal phototoxic dose (MPD) with it.
120
J Med Sci, Volume 44, No. 1, March 2012: 117 - 124
Compared with the more bulkier conventional
phototherapy, it is a lot more user-friendly and
has a more economical device maintenance.17
Indication and Targeted Phototherapy
Dosages
The following are indications and studied
targeted phototherapy dosage (TABLE 1):
Vitiligo
The use of UVB targeted phototherapy on
localized vitiligo aged 5-62 years old skin
phototype II-V, for as many as 30 therapy
sessions; twice a week, the first dose for the
thin skin was 50% MED and 75% MED for the
other, increased dose of 10-20 mJ/cm2 on each
session, with a result of good to very good
repigmentation on the face, medium repigmen-
tation on the neck, trunk and genital, but no
repigmentation on the upper nor lower extre-
mities.17 Asawanonda et al. compared targeted
BB UVB and targeted NB UVB in treating focal
and generalized stable vitiligo aged 16 years
old or more, given twice a week for 12 weeks
with an initial dose of 50% MED which
increased as much as 10%, repigmentation
obtained was about 26-50% in 6 out of 10
patients and the response toward BB-UVB and
NB-UVB was the same.25The use of a combinat-
ion between oral corticosteroid and 0.1%
tacrolimus ointment applied twice a day with
UVB targeted phototherapy given twice a week
for 5 months in 3-year old kids and adults with
segmental vitiligo, resulting in a good repig-
mentation, and minimum side effect which was
a transient erythema on the affected skin.30
Al-Otaibi et al.31 reported the use of
excimer laser on vitiligo with skin phototype
III to V, given twice a week for 13 weeks. The
treatment was started with 50 mJ/cm2 for the
eyes and genitalia, 100 mJ/cm2 for body lesions,
and increased by 50 mJ/cm2 in every session
until erythema appeared, for 25 sessions or
100% repigmentation, whichever achieved first.
The better result was seen on face, trunk and
extremities, whereas hands and feet gave a bad
response towards the therapy, side effects
occurred were erythema, blistering and burning.
Psoriasis
Narrowband UVB targeted phototherapy
has been studied on plaque psoriasis (skin
phototype II-1V; average Psoriasis Area
Severity Index (PASI) score 4,2), given once a
week for approximately 12 therapy sessions
with an initial dose of 90% MED and the dose
was increased of as much as 25% on each
session, a PASI score of 0,5 was obtained after
the treatment had been finished showing an 88%
improvement of the lesion without any side
effects.21
The use of UVB targeted phototherapy
compared to betamethasone valerate, with an
initial dose of 200 mJ/cm2, the dose increased
daily, given for 5 days in 3 weeks, both of the
groups experienced an improvement in PASI
score, but after a 2 week-observation the group
which used betamethasone valerate had more
recurrence rate than the group treated with
targeted UVB phototherapy.24 Meanwhile
another research conducted by Taneja et al.32
applied a BB-UVB with an intitial dose of 1
MED and an increasing dose of 20% for 12
weeks, a significant PASI score was obtained
compared to control group.
A study comparing a combination of topical
psoralen (0,001% 8-methoxypsoralen) and UVA
targeted phototherapy (PUVA) with psoralen
and UVB by Asawanonda et al. reported that
the use of a constant dose of UVA 5 J/cm2 once
a week for 12 weeks resulted in PASI score
improvement with an average amount of therapy
session of 4.75±3.5.33
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The use of excimer laser with an initial dose
of 1/3 MED which was increased based on
clinical response, given twice a week for 12
weeks. The results obtained were that 72%
achieved improvement for as much as 75% on
target plaque after the average of 6.2 times of
therapy, 84% achieved improvement for as
much as 75% on target plaque after the average
of 10 times of therapy, 50% achieved
improvement for as much as 90% on target
plaque after the average of 10 times of therapy
or less.28
The use of NB-UVB targeted phototherapy
on unresponsive to oral and topical treatment
of acrodermatitis continua of Hallopeau, a form
of acropustular psoriasis, with an initial dose
of 80% MED, increased dose was of 20% on
each session until reaching a maximum dose of
2000 mJ/cm2, given twice a week, remission
occurred with a minimal dystrophic nail plate
after session 36th, no side effect was found and
no recurrence on 12 month- follow-up.34
Eczema
Irradiation of acute eczema of the volar and
back of the hands using UVA1 for 15 times in 3
weeks showed that after the first week of
irradiation all patients except one patient
reported that they experienced a decreased
itchiness, and after the 15th irradiation, 10 out
of 12 patients showed a significant clinical
improvement.35 Those reports show that local
UVA irradiation on the eczema lesion gives a
good result.
A research done by Wollenschlager et al.
on 57 patients with resistant localized mild
atopic dermatitis using excimer laser showed
complete remission in 84% patients (48/57)
with a decreased in itchiness as the sign after
3-4 times therapy.36
Keloid
A research done by Asawanonda et al.
reported the use of UVA1 on 2/3 keloid lesion
for 6 weeks, with 22 therapy sessions given 4
times per week, resulting in a flattened and
softened lesion. In addition, histopathological
examination found that collagen and elastic
fibers returned back to normal.37
Hypopigmented scar or striae alba
The use of excimer laser with an initial dose
of MED minus 50 mJ/cm2), the dose increased
as much as 50 mJ/cm2 on each session, given
twice a week until 10 therapy sessions finished.
The results obtained were that the average of
visually assessed pigment correction
percentage, relative to control group was 61%
in patients with scar and 68% in patients with
striae after 9 therapy sessions, whereas the
average of pigmentation percentage using
calorimetric measurement relative to control
group was 101% in patients with scar and 102
% in patients with striae after 9 therapy
sessions.26
Oral lichen planus
Köllner et al.38 reported the use of excimer
laser on 2 cases of oral lichen planus
unresponsive towards the previous therapy,
given 3 times a week in 4 weeks (12 therapy
sessions) in case no.1 and 9 therapy sessions in
case no.2 with an initial dose of 75 mJ/cm2,
with a cumulative dose of 1.550 mJ/cm2 and
950 mJ/cm2, follow-up was done in the first,
second and fourth month after the therapy
finished, improved lesions and no recurrence
were the obtained results.39 Paseron et al.
reported the use of excimer laser on 4 cases of
erosive oral lichen planus, given twice a week
until 12 therapy sessions finished with an initial
dose of 50 mJ/cm2, the dose increased as much
as 50 mJ/cm2 on every 2 sessions until reaching
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a maximum dose of 200 mJ/cm2, one patient
was healed, meanwhile for the other 2 patients,
these therapies were only able to avoid disease
progression. Trehan and Taylor40 reported 9
cases oral lichen planus treated by excimer
laser, with a dose of 100 mJ/cm2 given once a
TABLE 1. Indications and dosages of targeted phototherapy
week, the results were that 5 patients improved
after 7 times therapy, whereas the other patients
gave intermediate or bad response towards the
therapy.Side effects of laser usage in oral lichen
planus were mild erythema39and erosion.38
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CONCLUSION
Targeted phototherapy is a therapeutical
modality that utilizes a device that can emit light/
UV spectrum of a specific wavelength, and
specifically targeted at the affected skin area in
the aim to overcome the disadvantages of
conventional phototherapy. Targeted photo-
therapy benefits the patients, the doctors and
also the operators. It is provided in a various
kind of device, and resulting in a satisfying
outcome in dermatological conditions and
diseases, some of which are vitiligo, psoriasis,
eczema, hypopigmented scar or striae alba, oral
lichen planus and many others.
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